10x Genomics announced two new research collaborations to identify blood-based biomarkers for autoimmune diseases using its Flex Apex technology. These partnerships aim to improve treatment selection and move beyond current indirect measures of immune activity, potentially enhancing the company's product utility and market position in diagnostics.
10x Genomics announced new research collaborations with Charité – Universitätsmedizin Berlin, DRFZ, and Seoul National University. These partnerships will utilize 10x Genomics' Flex Apex technology to identify blood-based biomarkers for autoimmune diseases like rheumatoid arthritis, lupus, psoriatic arthritis, and alopecia areata. This is a positive development for 10x Genomics as it validates their technology's utility in a significant medical field and could lead to broader adoption and future revenue streams from diagnostic applications. While not immediately revenue-generating, these collaborations enhance the company's scientific credibility and market potential in the long term, offering a strategic opportunity for growth in precision medicine.